

Docket No.: 1463920056XX
Client Reference No.: P2026
(PATENT)

POWER OF ATTORNEY
AND CORRESPONDENCE ADDRESS INDICATION FORM

I hereby appoint Practitioners associated with the Customer Number 25226 as our attorneys or agents to prosecute and to transact all business in the United States Patent and Trademark Office (USPTO) in connection with U.S. Provisional Application Serial No. 60/460,659 (filed April 4, 2003); U.S. Patent Application Serial Nos. 10/813,483 (filed on March 29, 2004), 11/549,194 (filed October 13, 2006), 11/549,220 (filed October 13, 2006), and 11/013,966 (filed December 16, 2004); and all patent applications claiming priority to the patent applications listed above (including all divisionals, continuations and continuations-in-part).

Please recognize or change the correspondence address for the above-identified applications to the address associated with the above-mentioned Customer Number 25226.

I am an Assignee of record. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

By executing the Power of Attorney, Novartis AG is allowing said Practitioners of the firm ("Morrison & Foerster"), to prosecute the above-identified patent applications and to prosecute any related matters that arise before the USPTO in the enforceable life of any patents issuing from the above-identified applications. Although the Power states that Novartis AG is appointing said Practitioners with "power of attorney" for the sole purpose of prosecuting the matters arising before the USPTO in connection with the patent applications, that appointment is understood solely in light of Novartis AG's ownership interest in the applications. So, despite the use of the phrase "power of attorney," Novartis AG and said Practitioners and Morrison & Foerster mutually agree and confirm that this executed power of attorney does not create any attorney-client relationship, actual or prospective, between Novartis AG and said Practitioners and/or Morrison & Foerster, or, for that matter, between said Practitioners and/or Morrison & Foerster and any other person with respect to


Docket No.: 1463920056XX
Client Reference No.: P2026
(PATENT)

the patent applications. Genentech, Inc, will remain said Practitioners and Morrison & Foerster's sole client in respect of the above-identified patent applications and patents issuing therefrom.

Dated: May 30, 2008

Respectfully submitted,

By


Name: Leslie Fischer
Title: Patent Attorney
on behalf of
Novartis AG